I find this discouraging. Basically, numerous trials already show that high concentrations of EPA lower the progression and impact of Alzheimer's and yet, judging from the flat sales of Vascepa and Vascepa generics over the last year or two, it's clear that no new doctors are saying: "Hey, all of these trials seem to show that high concentrations of EPA is really good for patients with Alzheimer's, the potential for it, or heart issues. Maybe I should start prescribing it to more of my patients." Is this collective malpractice by just about all the doctors in the U.S.?
Do medical journalists across the country and world even know about these studies or do they only learn about EPA from Dr. Nissen?
And it looks like there are already trials that have taken place on even more patients than the few in the BRAVE trial and the results have been outstanding. So even with great results, will the BRAVE trial outcome be like all of these other trees that fell in the Alzheimer's forest that nobody saw or heard?
Can BRAVE results be better than these?:
• Patan et al., 2021 described results from 310 healthy young adults who were given either ‘EPA-rich
oil’ (900 mg EPA + 360 mg DHA), ‘DHA-rich oil’ (900 mg DHA + 270 mg EPA) or placebo (olive oil) for
26 weeks. The study examined cognition, memory consolidation, and prefrontal cortex hemoglobin
oxygenation. The authors found that the group taking the EPA-rich formulation performed better
than placebo or DHA-rich group on global accuracy and speed on cognition assessments, and that
the EPA-rich formulation group had improved accuracy of memory in comparison to the DHA-rich
group.
• DM van Lent et al., 2021 performed a prospective analysis of 1,264 non-demented seniors in
Germany who were 84 (+/- 3) years old. The study authors followed patients for 7 years and
investigated the association of several fatty acids (EPA, DHA, ALA, LA, DGLA, and AA) in serum with
all-cause dementia and Alzheimer’s disease. They found that higher concentrations of EPA were
associated with decreased risk of AD (HR=0.76; 95% CI 0.63 – 0.93).
AI
Market Data 
Markets 
